News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
699,935 Results
Type
Article (39736)
Company Profile (248)
Press Release (659951)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204193)
Career Advice (2008)
Deals (35423)
Drug Delivery (95)
Drug Development (81053)
Employer Resources (172)
FDA (16189)
Job Trends (14864)
News (345236)
Policy (32546)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49447)
ALS (95)
Alzheimer's disease (1383)
Antibody-drug conjugate (ADC) (132)
Approvals (16187)
Artificial intelligence (264)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11637)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (176)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (290)
Cancer (2315)
Cardiovascular disease (179)
Career advice (1677)
Career pathing (30)
CAR-T (155)
Cell therapy (435)
Cervical cancer (20)
Clinical research (66088)
Collaboration (856)
Company closure (2)
Compensation (565)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (250)
Cystic fibrosis (102)
Data (2322)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6379)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (102)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (87019)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112646)
Executive appointments (741)
FDA (17566)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (766)
Gene editing (109)
Generative AI (20)
Gene therapy (313)
GLP-1 (719)
Government (4429)
Grass and pollen (4)
Guidances (158)
Healthcare (18819)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (124)
Indications (29)
Infectious disease (2735)
Inflammatory bowel disease (143)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (98)
Interviews (312)
IPO (16526)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (325)
Lymphoma (157)
Machine learning (9)
Management (58)
Manufacturing (324)
MASH (77)
Medical device (13383)
Medtech (13388)
Mergers & acquisitions (19468)
Metabolic disorders (707)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (94)
Neuropsychiatric disorders (27)
Neuroscience (1938)
NextGen: Class of 2025 (6513)
Non-profit (4480)
Now hiring (40)
Obesity (371)
Opinion (205)
Ovarian cancer (81)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (151)
Partnered (22)
Patents (242)
Patient recruitment (115)
Peanut (46)
People (57346)
Pharmaceutical (63)
Pharmacy benefit managers (19)
Phase I (20591)
Phase II (29110)
Phase III (21674)
Pipeline (1367)
Policy (147)
Postmarket research (2563)
Preclinical (8756)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (384)
Real estate (5907)
Recruiting (65)
Regulatory (22326)
Reports (47)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (131)
Series B (87)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (49)
The Weekly (30)
Vaccines (699)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (147)
Last 7 days (963)
Last 30 days (3075)
Last 365 days (32481)
2025 (11809)
2024 (35219)
2023 (40077)
2022 (51174)
2021 (55710)
2020 (54084)
2019 (46540)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37554)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29270)
2010 (27332)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37884)
Australia (6192)
California (6398)
Canada (2062)
China (539)
Colorado (272)
Connecticut (280)
Delaware (158)
Europe (81396)
Florida (954)
Georgia (213)
Idaho (57)
Illinois (546)
India (25)
Indiana (321)
Iowa (11)
Japan (171)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (919)
Massachusetts (4754)
Michigan (225)
Minnesota (404)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1789)
New Mexico (28)
New York (1800)
North Carolina (986)
North Dakota (8)
Northern California (2821)
Ohio (211)
Oklahoma (14)
Oregon (34)
Pennsylvania (1424)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (25)
South Dakota (1)
Southern California (2405)
Tennessee (105)
Texas (950)
United States (23965)
Utah (188)
Virginia (151)
Washington D.C. (64)
Washington State (563)
West Virginia (3)
Wisconsin (56)
699,935 Results for "ajinomoto althea inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea
April 24, 2025
·
3 min read
Press Releases
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
May 7, 2025
·
3 min read
Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium
Ajinomoto Co., Inc. launched a new version of its StemFit™ iPSC expansion medium.
March 26, 2024
·
3 min read
Deals
Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1
Ajinomoto Co., Inc. and Forge Biologics, announced that they have entered into a definitive agreement by which Ajinomoto Co., will acquire Forge, a leading manufacturer of genetic medicines, in an all-cash deal for $620 million.
November 13, 2023
·
4 min read
Ajinomoto Co. Launches Silicon Valley CVC HQ to Grow U.S. Investments, Adds New Portfolios
Ajinomoto Co., Inc., the Japan-based multinational corporation covering food, healthcare and electronic materials, and built on “AminoScience,” has expanded its corporate venture capital arm with new U.S. headquarters to grow its investments in U.S. and global companies.
February 13, 2024
·
2 min read
Biotech Beach
Ajinomoto Bio-Pharma Services Garners Six ‘CDMO Leadership Awards,’ Further Establishing Its Industry Excellence
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, received CDMO Leadership Awards in all six categories - Capabilities, Compatibility, Expertise, Quality, Reliability, and Service for both the Overall and Big Pharma respondent groups.
March 12, 2024
·
2 min read
Business
Ajinomoto Bio-Pharma Services Announces Leadership Changes at US Facility
Ajinomoto Bio-Pharma Services today announced leadership changes at the company’s site in San Diego, effective immediately.
May 18, 2023
·
3 min read
Business
Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
Ajinomoto Co., Inc. (“Ajinomoto Co.”) today announced a license agreement with Exelixis, Inc. (“Exelixis”) to incorporate AJICAP®, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis’ antibody-drug conjugate (ADC) programs.
January 10, 2023
·
4 min read
FDA
Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line
Ajinomoto Bio-Pharma Services is pleased to announce that the United States Food and Drug Administration (FDA) has approved the company’s high potency vial line to manufacture a commercial product.
April 19, 2023
·
1 min read
Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase
Ajinomoto Bio-Pharma Services is pleased to announce the development of a new enzyme for double strand oligonucleotide formation with high productivity.
February 22, 2023
·
3 min read
1 of 69,994
Next
